Clinical Trial Update: Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing monthly versus PRN ranibizumab in neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Retina Macula Institute | Conditions: Neovascular Age Related Macular Degeneration | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-09-02